Dr. Sridhar Ramaswamy is an entrepreneur in residence at GV. His focus is on envisioning next-generation oncology companies that will transform cancer care.
Most recently, Dr. Ramaswamy was Senior Vice President and Head, Research & Early Development at TESARO. He was a member of the TESARO executive leadership team that spearheaded TESARO’s successful acquisition and integration by GlaxoSmithKlein in 2019. Dr. Ramaswamy served on its Executive Leadership Team governing research, development, commercial, and corporate activities.
Before TESARO, Dr. Ramaswamy specialized in caring for patients with breast cancer, GI cancers, and leukemias as a practicing oncologist for twenty years at the MGH Cancer Center and Dana-Farber Cancer Institute. Dr. Ramaswamy was Associate Professor of Medicine, Tucker Gosnell Investigator, Samana Cay Scholar, and Director, Center for Cancer Systems Discovery at the Massachusetts General Hospital Cancer Center, Harvard Medical School, and the Broad Institute.
After serving as Chief Resident in Medicine at Columbia-Presbyterian Medical Center, Dr. Ramaswamy completed clinical fellowships in Medical Oncology & Hematology at the Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Massachusetts General Hospital in Boston. He also completed advanced research fellowships at the National Institutes of Health, Dana-Farber Cancer Institute / Harvard Medical School, and Whitehead Institute / MIT Center for Genome Research.
Dr. Ramaswamy is a Fellow of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the American Society for Clinical Investigation.